All In Biotech

Drug Trial Radar · NCT06241183

Famotidine and Antacids for Treatment of Dyspepsia

Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 9, 2023

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Stony Brook UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Conditions

  • Dyspepsia
  • GERD
  • Acid Reflux

Interventions

  • Intravenous FamotidineDrug

    Patients in this group will receive 20mg IV Famotidine.

  • Oral Maalox/ MylantaDrug

    Patients in this group will receive 30 ml Maalox/ Mylanta.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Verbal Numerical Pain ScoreTime frame: at 1 hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.